Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC).
Clin Transl Radiat Oncol
; 33: 115-119, 2022 Mar.
Article
en En
| MEDLINE
| ID: mdl-35243022
ICI, Immune Checkpoint Inhibitors; NSCLC, Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; OS, Overall Survival; Oligoprogression; PFS, Progression Free Survival; PTC, Planning Target Volume; RECIST, Response Evaluation Criteria in Solid Tumor; SABR, Stereotactic Ablative Radiotherapy; Stereotactic body radiation therapy; TKIs, Tyrosine Kinase Inhibitors
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
Aspecto:
Patient_preference
Idioma:
En
Revista:
Clin Transl Radiat Oncol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Canadá
Pais de publicación:
Irlanda